Insulin/GLP-1 Receptor Agonists
In order to decrease the number of medications for diabetes that a patient needs to take, combination products of basal insulin and GLP-1 receptor agonists, were approved by the FDA in 2016. IGlarLixi
(Soliqua® 100/33) contains 100 units of insulin glargine and 33mcg of lixisenatide (a novel GLP-1 RA approved in 2016) per 1mL.19 Recommended starting dose of Soliqua® is 15 units (15 units insulin glargine/5 mcg lixisenatide) given subcutaneously once daily for patients inadequately controlled on less than 30 units of basal insulin or on lixisenatide.19 (Table 2) Starting dose of 30 units (30 units insulin glargine/10 mcg lixisenatide) given subcutaneously once daily can be used for patients inadequately…show more content… controlled on 30 to 60 units of basal insulin.19 (Table 2) Soliqua® should be injected once daily within the hour prior to the first meal of the day.19 (Table 2) Maximum daily dosage is 60 units (60 units of insulin glargine and 20 mcg of lixisenatide).19 (Table 2) Soliqua® 100/33 pen delivers doses from 15 to 60 units with each injection.19 Alternative therapy should be considered for patients who require a Soliqua®
100/33 daily dosage below 15 units or over 60 units.19 IDegLira (Xultophy® 100/3.6), contains 100 units of insulin degludec and 3.6mg of liraglutide per 1mL.20
Recommended starting dosage of Xultophy® is 16 units (16 units of insulin degludec and 0.58 mg
